Genotype-Phenotype Correlation of Maternally Inherited Disorders due to Mutations in Mitochondrial DNA  by Thajeb, Peterus et al.
Historical Overview
The discovery of DNA in human mitochondria by Nass
and Nass in 1963 [1], followed by the successful 
complete sequencing of human mitochondrial DNA
(mtDNA) almost two decades later by Anderson et al
[2], heralded a new era of mitochondrial medicine.
mtDNA is a circular DNA of 16,569 base pairs, with
one light strand and one heavy strand. Absence of his-
tone structure and inefficient DNA repair render it sus-
ceptible to “genetic error” or mutation. Mutations of
mtDNA in humans cause many disorders, collectively
known as oxidative phosphorylation (OXPHOS) disor-
der [3], or mitochondrial disease (MtD) [4–9]. The
concept of mitochondrial cytopathy emerged from a
report by Luft et al in 1962 [10], which described a
young woman with hypermetabolism of nonthyroid
origin, morphologically abnormal muscle mitochondria
and “loose coupling” of oxidation and phosphorylation
of the isolated muscle mitochondria.
The histopathologic findings of ragged red fibers (RRF)
on modified Gomori trichrome histochemical stain was
then described by Engel and Cunningham in 1963 [11].
The ultrastructural alterations of mitochondria of the
skeletal muscles of patients with MtD/OXPHOS were elu-
cidated in the reports by Shy and Gonatas, and described
as pleoconial myopathy and megaconial myopathy in 1964 and
1966, respectively [12,13]. In 1977, the nosology of
mitochondrial encephalomyopathy was introduced [14]. This
terminology remains widely used nowadays, although
the brain and muscles are not the only two organ sys-
tems involved in most cases of mitochondrial disorders.
Affections of OXPHOS involve multiple organs, such
as the brain, eyes, ears, heart, liver, kidneys, endocrine
systems, integument, peripheral nerves, muscles and so
on. A dozen clinical syndromes have been reported
(Table), and they are called the syndromic MtD/
syndromic OXPHOS disease. Genotypic and phenotypic
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heterogeneity are notorious to MtD/OXPHOS disease
[9,15]. However, non-syndromic neurologic manifesta-
tions or secondary forms of central nervous system (CNS)
dysfunction may also occur. Regardless of whether it 
is syndromic or non-syndromic MtD, mtDNA mutations
are frequently caused by mtDNA rearrangement [16],
mtDNA deletion [17–20], duplication, or point muta-
tion [21–24]. Dual point mutations and large-scale dele-
tion plus a critical point mutation are rare [25,26].
Genotype–Phenotype Correlation of
Human Syndromic MtD
Mitochondrial myopathy, encephalopathy, lactic
acidosis and stroke-like episodes (MELAS)
MELAS syndrome [27] is the most common syndromic
manifestation of mitochondrial encephalomyopathies
that occur in all age groups [24,28]. The clinical course
of MELAS is slowly progressive with stepwise deterio-
ration. The severity of lactic acidosis correlates with the
severity of neurologic deficit [29]. Seizures are frequent
in patients with MtD. However, intractable epilepsy,
epilepsia partialis continua or Koshevnikov syndrome
may occur in patients with MELAS syndrome [30].
Calcification of bilateral basal ganglia is a frequent
neuroimaging finding in patients with MELAS [31].
The stroke-like episodes often involve the parieto-
occipital lobes and posterior brain regions crossing
two or more arterial territories [32]. Deep white matter
changes in watershed areas and subcortical regions
are common in patients with MELAS [33,34]. Reversible
vasogenic edema, focal brain ischemia, neuronal meta-
bolic derangement and cellular energy failure have
been accrued to the characteristic lesions seen on brain
magnetic resonance imaging (MRI) [35]. Findings from
brain single photon emission computed tomography in
patients with MELAS may be anedoctal. Focal hyper-
perfusion (hyperemia) [36] or regional hypoperfusion
[37] may be seen at different stages of the disease. The
latter has been proposed to be due to a “mitochondrial
vasculopathy” and can be seen in MELAS/A3243G fam-
ily members who manifest clinically as chronic progres-
sive external ophthalmoplegia (CPEO) (CPEO/A3243G)
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Table. Genotype–phenotype correlation of oxidative phosphorylation (OXPHOS) diseases*
OXPHOS phenotypes Genotypes (mt gene defect) References
CPEO mtDNA rearrangement 16
mtDNA del, tRNALeu (A3243G, spm), MTTN*CPEO5692G 16, 19, 20, 26
KSS mtDNA rearrangement, del 16, 19, 20
tRNALeu (spm) 36, 39
LS NARP, SURF1 (spm) 56–61
ND3, ND5, ATPase 6 (spm)
LHON G11778A (spm), G3460A, G15257A, ND1, 4, 6 (spm); 63–70
dual mutations
MELAS tRNALeu (A3243G, spm) 23–43
3302, 3303, 3243, 3250, 3260 (spm), tRNALeu and tRNAGlu 38–43
dual mutations
MERRF tRNALys (A8344G, spm) 26, 46, 47
T8356C, POLG (spm) 48
MNGIE Thymidine phosphorylase, ND5 spm 71–75
OPSM 3,399 bp del plus T5814C mutation 26
MCM tRNALeu (spm) 77
Overlap syndrome
CPEO/MELAS A3243G (spm) 15, 50
CPPDM/MELASDM A3243G (spm) 15
KSS/Lowe syndrome mtDNA del 53
LHON/MELAS ND5 (spm) 80
LS/MELAS ND5 (missense mutation) 81
MELAS/MERRF tRNAHis, tRNALys, tRNASer (spm) 79
*Refer also to references 3, 6, 8, 9, 17–29, 35, 44, 49, 65, 66 and 76. CPEO = chronic progressive external ophthalmoplegia; mtDNA = mitochondrial DNA;
del = deletion; spm = single point mutation; KSS = Kearns–Sayre syndrome; LS = Leigh’s syndrome; LHON = Leber’s hereditary optic neuropathy;
MELAS = mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episode; MERRF = myoclonic epilepsy, ragged red fibers; MNGIE = mitochondrial
neurogastrointestinal encephalomyopathy; OPSM = oculopharyngeal somatic myopathy; MCM = myopathy/cardiomyopathy.
[37]. Dementia with cortical atrophy is a late conse-
quence of MELAS.
A-to-G transition in the tRNALeu(UUR) gene at nucleo-
tide position (np) 3243 is the most frequent mutation
(> 90% of patients) found in both Caucasians and
Orientals with MELAS (MELAS/A3243G) [23,24,38–43].
However, single point mutation at np 3271 (MTTL1*
MELAS 3271C), at np 3302, 3303, 3250 and 3260
[8,38,43,44], and double mutations at tRNALeu and
tRNAGlu [25] have also been reported. The mutant genes
of MELAS were amplified through generations [45]
and anticipation may occur.
Myoclonic epilepsy and ragged red fibers (MERRF)
MERRF [9,24,46–49] occurs more often in children
and young adults. Photosensitive myoclonus, myopa-
thy and epilepsy are cardinal features. Myopathy occurs
in 70% of patients carrying the A8344G mutation
[26]. RRF on histopathologic study of muscle biopsy is
an important clue to the diagnosis. However, it could
be absent in some proven cases. Ataxia may occur in
50% of patients. Short stature, optic neuropathy and
lipomata are uncommon associations. The A8344G
mutation in the tRNALys gene occurs in 80–90% of
patients with MERRF [24,46]. T-to-C transition at np
8356 (T8356C) in the tRNALys gene [47] and point
mutation in the tRNASer gene [48] have also been
reported.
Chronic progressive external ophthalmoplegia (CPEO)
CPEO [7,8,16–20,37,49,50] can sometimes be mis-
diagnosed as ocular myasthenia gravis or other forms
of congenital ocular myopathy. Disproportionate paral-
ysis of the extraocular muscles and levator palpebrae,
and lack of diurnal change of the ophthalmoparesis are
the key features to distinguish CPEO from myasthenia
gravis. CPEO with carnitine deficiency may overlap with
MELAS [50]. mtDNA rearrangements and large-scale
deletion of mtDNA are common in CPEO [16,19,20]. A
combination of 3,399 bp deletion and T5814C muta-
tion has been reported in a Taiwanese patient with
slowly progressive oculopharyngeal somatic myopathy
resembling CPEO plus syndrome [26]. Heteroplasmic
A3243G may also manifest clinically as CPEO with diabe-
tes mellitus (CPPDM3243) in one affected family mem-
ber and MELAS with diabetes mellitus (MELASDM
3243) in another (CPPDM3243/MELASDM3243 syn-
drome) [15].
Kearns–Sayre syndrome (KSS)
KSS [51] has cardinal features of pigmentary retinopa-
thy, CPEO, cerebellar atrophy and cerebral white mat-
ter lesions [32–34]. Additional features are cardiac
arrhythmia, mental retardation and multiple endocrine
disorders. Onset of symptoms usually occurs in the
teens and the prognosis is poor [49]. mtDNA deletion
[16,19,20] occurs in > 70% of patients with KSS. Single
point mutation at tRNALeu has also been reported
[36,39,52]. Approximately 99% of mitochondrial dele-
tions occur within the common area between base
pair at the position 5000 to 16000. Deletions are of
different sizes in different people [17]. Rapidly dividing
cells lose the deleted mitochondria over time. A sporadic
somatic cell mutation (germ line is normal) and mito-
chondrial duplication occur rarely. The diagnostic crite-
ria for KSS includes: CPEO, pigmentary retinopathy, and
one of the three other features such as complete heart
block, cerebrospinal fluid (CSF) protein ≥ 100 mg/dL
and ataxia. A variety of some other associated features
are short stature, deafness, dementia, myopathy, lac-
tic acidosis and endocrinopathy. KSS with Lowe syn-
drome [53] and other overlap syndrome (see below)
may occur.
Leigh’s syndrome (LS)
LS [54] is a genetic disorder with mendelian recessive
inheritance. It affects males more often than females
[54–60]. Based on the age at onset of disease, it can
be divided into four types. The “infantile form” [54,55]
occurs before the age of 1 year, the “early childhood
form” develops by the age of 2 years, the “adolescent
form” in the first two decades of life, and the “chronic
form” [56,57]. Clinical features include: (1) psychomo-
tor developmental arrest; (2) ataxia, hypotonia, other
cerebellar signs; (3) loss of vision; (4) dysphagia and
other pyramidal signs; (5) central neurogenic hyper-
ventilation; (6) neuropathic signs. Computed tomog-
raphy (CT) of the brain show symmetrical low density
in the lenticular nucleus, called “holes in the brain”.
CSF may be abnormal with elevated CSF protein. LS has
been considered an inborn error of gluconeogenesis
[58]. A variety of metabolic abnormalities can be found,
such as deficiency of mitochondrial enzyme, thiamine
triphosphate phosphoryltransferase (TTP) in the
brain, deficiency of pyruvate carboxylase in the liver,
decreased Krebs cycle activity, deficiency of pyruvate
dehydrogenase and endophine system, and accumula-
tion of pyruvate and lactic acids [58]. Co-enzyme Q
[59] and antioxidants [60] may be useful for some
patients with LS and encephalopathy. LS has a diverse
genetic basis. Single point mutations in the NARP,
SURF1, ND3, ND5, and ATPase 6 genes have been
reported (Table). NARP mutation accounts for about
20% of LS, especially when the percentage mutant load
is high. Certain cases have a point mutation, T-to-C
transition, at np 9176 [61].
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Autopsy of the brain and spinal cord of an infant
with LS [54] shows: (1) vascular (capillary) or endothe-
lial proliferation with less prominent neuronal changes
(necrotizing encephalopathy); (2) degenerative changes
in neuronal processes and myelin sheath resulting in
loosening of neuropil; (3) astrocytosis with microglial
proliferation; (4) mitochondrial changes. LS predomi-
nantly affects gray matter in a symmetrical pattern,
especially involving the basal ganglia, diencephalon,
substantia nigra, cerebellum, brainstem nuclei and
spinal cord [54,62]. It may rarely affect the centrum
semiovale and the peripheral nervous systems. It differs
from Wernicke’s encephalopathy in that it involves the
substantia nigra more extensively and involves the mam-
millary bodies much less. Histopathology of the skele-
tal muscles shows RRF and abnormal mitochondria.
Cardiomyopathy, renal tubular dysfunction and growth
hormone deficiency may also be present.
Leber’s hereditary optic neuropathy (LHON)
LHON is the most common cause of maternally inherited
blindness that occurs in adolescence. Painless bilateral
vision loss of subacute onset is the main feature. Brain
MRI shows white matter changes resembling multiple
sclerosis [33,34,63]. Involuntary movements such as
chorea, dementia [64] and cardiomyopathy may occur
[65,66]. At least eight major mutations have been rec-
ognized [63–70]. It is estimated that 75–95% of LHON
are caused by mutations in the following three genes:
G11778A (40–60%) and G3460A (20%) that affect
complex I, and G15257A (15%) that affect complex III.
Dual mutations have been reported [68]. Phosphorous
magnetic resonance spectroscopy may be abnormal 
in patients with LHON [70].
Mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE) syndrome
MNGIE has also been recognized as POLIP (polyneu-
ropathy, ophthalmoplegia, leukoencephalopathy and
intestinal pseudo-obstruction) [71–74]. Dysmotility
and paresis of the gastrointestinal tract with episodic
vomiting and progressive malnutrition may lead to death
in early or middle age life [71]. Postmortem pathologic
studies showed neuronal loss of the celiac ganglion,
fibrosis of the mesenteric and Auerbach plexuses, leuko-
encephalopathy [71–74] and neuromyopathy. Multiple
mtDNA deletion, point mutation in the thymidine phos-
phorylase gene and missense mutation in the ND5 gene
have been reported [71–75].
Neuropathy, ataxia, retinitis pigmentosa (NARP)
NARP is characterized by neuropathic weakness of the
limbs, neuropathic sensory deficit, ataxia and retinitis
pigmentosa [60,76]: T8993G transition with leucine to
arginine substitution and ATPase subunit 6 (complex V)
defect [60].
Myopathy/cardiomyopathy syndrome
Myopathy/cardiomyopathy syndrome is rare, and it is
caused by a point mutation at A3260G in tRNALeu, or
T3250C in tRNALeu [77]. Mitochondrial myopathy may
also be caused by chronic use of zidovudine [78].
Overlap syndromes
Overlap syndromes with diverse combinations, such as
KSS/CPEO [19], MELAS/MERRF [79], LHON/MELAS
[80], CPEO/MELAS [50], CPPDM/MELASDM [15],
Leigh-MELAS [81] and KSS/Lowe [53] overlap syn-
dromes and many others have been described.
Non-syndromic Manifestations 
of MtD
MtD/OXPHOS disease may present with a number of
non-syndromic manifestations ranging from an isolated
neurologic symptom or sign to various combinations
with non-neurologic features, e.g. involuntary move-
ments such as chorea, tremor, hemiballism, ataxia and
dystonia, migraine-like headache, neuropsychiatric mani-
festations and endocrine disorders such as hypopitu-
itarism, deficiency of secretion of anti-diuretic hormone,
hypogonadism and diabetes mellitus. Some other 
features of CNS manifestations may be secondary to
organ failure, such as hepatic encephalopathy and
nephropathy.
Regardless of the mechanisms of the underlying
genetic defects, a common molecular pathway is either
a loss-of-function or a gain-of-a-new-function of the
mitochondrial machinery that results in uncoupling of
cellular oxidative phosphorylation. Apart from mtDNA
point mutation, mtDNA deletion or duplication, nuclear
DNA and mtDNA (nDNA/mtDNA) communication syn-
drome, and mtDNA depletion syndrome (MDS) may
occur. nDNA/mtDNA communication syndrome is an
autosomal dominant disorder with multiple nDNA/
mtDNA deletions, however, MDS is an autosomal reces-
sive disorder.
Mitochondrial depletion syndrome (MDS)
MDS most likely involves the brain, liver, kidney and
muscles. The hepatocerebral form has been reported
to be due to DGK gene mutations [82] and mtDNA
copy number depletion. Mutation of the SUCLA2 gene
encoding succinyl coenzyme A synthase of Krebs cycle
has been reported [49].
Molecular Mechanisms Explaining the
Heterogeneity of the Phenotypes of
Mitochondrial Disorders
Heterogeneity of the clinical expressions of mtDNA
defects can be explained by the following mechanisms.
First, widespread distribution of the mutant mtDNA in
different tissues varies among individuals [83]. The pro-
portion of mutant mtDNA (percentage mutant load) in
different tissues of the affected individual varies as well
[5,8,16,24,40,84]. Phenotypes depend on the mutant
load of different tissues [24,40,84]. It has been shown
that the mutant load of muscles, but not of blood
cells, of patients with A3243G mutation correlates with
the occurrence of several clinical features [24]. Positive
correlation between the frequencies of occurrence of the
clinical features of recurrent stroke, dementia, epilepsy,
and ataxia and percentage mutant load has been
observed in the muscles. The higher the percentage of
mutant load in muscles, the higher the frequency of
occurrence of these specific features [24]. Conversely,
an inverse correlation is valid for the manifestations of
CPEO, myopathy and deafness (the higher percentage
of A3243G mutant load has the lower frequency or
percentage of occurrence of these features) [24].
Second, an intercellular heteroplasmy (cells carry both
mutant and wildtype mtDNA) [85,86] and mosaicism
exists. Different cells have different thresholds (safety
margin) to the effects of mutant load. The amplifica-
tion of mutant mtDNA through successive generations
has been documented [45]. Finally, interactions among
environmental factors and genes, communication and
signal transduction between nDNA and mtDNA, and
many other unknown modifying factors modulate the
expression of the primary mtDNA defect.
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